Imricor Medical Systems
Development of MRI-compatible medical devices to carry out MRI-guided cardiac catheter ablation procedures.
Short position
Imricor Medical Systems (ASX:IMR) has 0.66% of its shares on issue reported as short positions as of 5 Oct 2026, or about 2,373,293 shares. Over the past 30 days that figure has risen 0.50 percentage points, and over 90 days it has risen 0.59 percentage points. IMR is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Imricor Medical Systems (IMR) financials
Results, ratios and statements
Latest result
Year to 31 Dec 2025 (FY25) vs FY24, figures in USD, the reporting currency
- Revenue
- 292.3Kvs 959.4K (FY24)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −25.3Mvs −29.7M (FY24)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −0.080T (source: Derived: trailing 12 months at year end)vs −0.13 (FY24)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −69.5%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Key ratios
Year to 31 Dec 2025 (FY); balance sheet at 31 Dec 2025; prices to 9 Oct 2026
- Gross margin
- −695.7%
- Operating margin
- −8,082.0%
- Net margin
- −8,661.6%
- FCF margin
- −6,676.3%
- ROE
- n/a
- ROA
- −75.2%
- FCF conversion
- n/a
- Net debt (excl. leases)
- USD 5.5M
- Net debt / EBITDA
- n/a
- Current ratio
- 2.5×
- Interest cover
- −5,666.7×
- Cash dividends paid / net profit
- n/a
- Market cap
- $444.5M
- P/E
- n/a (reports in USD)
- P/B
- n/a (reports in USD)
Ratios use the reporting currency (USD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | 292.3K | 959.4K | 615.6K | 816.0K |
| Gross profit | −2.0M | −924.1K | −1.1M | −1.5M |
| Operating income | −23.6M | −17.1M | −17.6M | −18.0M |
| EBITDA | −24.5M | −28.9M | −21.9M | −16.5M |
| EBIT | −25.3M | −29.7M | −22.6M | −17.2M |
| Interest expense | 4.2K | 20.1K | 47.9K | 177.9K |
| Pretax income | −25.3M | −29.7M | −22.6M | −17.4M |
| Tax | 0 | 0 | 0 | 0 |
| NPAT | −25.3M | −29.7M | −22.6M | −17.4M |
| Net interest income | 1.2M | 237.7K | 15.1K | −69.9K |
| EPS basic | −0.080T (source: Derived: trailing 12 months at year end) | −0.13 | −0.14 | −0.12 |
| EPS diluted | −0.080T (source: Derived: trailing 12 months at year end) | −0.13 | −0.14 | −0.12 |
| Shares | 320.9M | 270.2M | 174.4M | 156.3M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Q2 CY2026 Quarterly Activities Report & Form 10-Q SubmissionQuarterly Report10 Aug 2026via asx_announcements
- Imricor Q1 CY26 Quarterly Activities Report and Appendix 4CQuarterly Report28 Apr 2026via asx_announcements
- Annual Report to shareholdersAnnual Report27 Mar 2026via asx_announcements
- Appendix 4E and FY25 Financial AccountsAnnual Results25 Feb 2026via asx_announcements
- Imricor Q4 CY25 Quarterly Activities Report and Appendix 4CQuarterly Report28 Jan 2026via asx_announcements
- Imricor Q3 CY25 Quarterly Activities Report and Appendix 4CQuarterly Report22 Oct 2025via asx_announcements
- Appendix 4D and Half Year Report & AccountsHalf Year Results26 Aug 2025via asx_announcements
- Imricor releases Half Year Results for 1H 2025Half Year Results26 Aug 2025via asx_announcements
- Imricor Q2 CY25 Quarterly Activities Report and Appendix 4CQuarterly Report28 Jul 2025via asx_announcements
- Imricor Q1 CY25 Quarterly Activities Report and Appendix 4CQuarterly Report23 Apr 2025via asx_announcements
Showing 10 of 73 reports